Pricing Log in Create free account
Friday 6 November 2026 Export IONS’s income statement to Excel — free account

Ionis Pharmaceuticals, Inc.

IONS Healthcare Biotechnology

Ionis Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $943.7 million, up 33.8% from fiscal 2024.

Revenue
−40.7%
EPS
−188.5%
Free cash flow
+299.3%
Total debt
+116.0%

Quarter to June 2026, against a year earlier

39.48 0.68 +1.75%
Market cap
$6.5B
P/E
0.0×
Fwd P/E
−12.2×
Dividend yield
—
F-score
4/9
Altman Z
2.12
Beneish M
−3.13
Dividend safety
n/a
Overview Business Profile
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Ionis Pharmaceuticals, Inc. 10-Q filed Jul 29, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 5:05 PM ET · Document on sec.gov · Filing index

Red flags

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Apr 29, 2026: 8 added · 5 removed · 23 modified; 4 with only figures updated

  1. Modified · Overview

    With twomultiple independent commercial launches now underway, we have transitioned into a fully integrated commercial-stage biotechnology company. We currently have seven marketed medicines to treat serious diseases: TRYNGOLZA (olezarsen), DAWNZERA (donidalorsen), WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). In addition, we are positioned to independently launch two medicinesFollowing approval by the U.S. Food and Drug Administration, or FDA, olezarsen in June 2026, we independently launched TRYNGOLZA for the treatment of severe hypertriglyceridemia, or sHTG. In addition, and we are on track to independently launch zilganersen for Alexander disease, or AxD, in 2026, assuming regulatory approval. We also have a rich innovative pipeline across our focus areas of neurology, cardiometabolic diseases and select areas of high patient needs. We currently have threetwo wholly owned medicines and sixeight partnered medicines in Phase 3 development, including obudanersen for Angelman syndrome, or AS, which we advanced into a has completed enrollment of the Phase 3 study in the second quarter of 2025. We also have additional medicines in early and mid-stage development.